Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy RAPT Therapeutics stock

Own RAPT Therapeutics stock in just a few minutes.

RAPT Therapeutics, Inc is a biotechnology business based in the US. RAPT Therapeutics shares (RAPT) are listed on the NASDAQ and all prices are listed in US Dollars. RAPT Therapeutics employs 68 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in RAPT Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – RAPT – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

RAPT Therapeutics share price

Use our graph to track the performance of RAPT stocks over time.

RAPT Therapeutics shares at a glance

Information last updated 2021-04-23.
52-week range$13.36 - $41.86
50-day moving average $21.27
200-day moving average $23.58
Wall St. target price$36.50
PE ratio 0.6299
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.89

Buy RAPT Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy RAPT Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is RAPT Therapeutics under- or over-valued?

Valuing RAPT Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of RAPT Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

RAPT Therapeutics's P/E ratio

RAPT Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 1x. In other words, RAPT Therapeutics shares trade at around 1x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

RAPT Therapeutics financials

Revenue TTM $5 million
Gross profit TTM $5 million
Return on assets TTM -32.67%
Return on equity TTM -59.66%
Profit margin 0%
Book value $4.21
Market capitalisation $517.9 million

TTM: trailing 12 months

Shorting RAPT Therapeutics shares

There are currently 908,919 RAPT Therapeutics shares held short by investors – that's known as RAPT Therapeutics's "short interest". This figure is 0.7% up from 902,726 last month.

There are a few different ways that this level of interest in shorting RAPT Therapeutics shares can be evaluated.

RAPT Therapeutics's "short interest ratio" (SIR)

RAPT Therapeutics's "short interest ratio" (SIR) is the quantity of RAPT Therapeutics shares currently shorted divided by the average quantity of RAPT Therapeutics shares traded daily (recently around 192160.46511628). RAPT Therapeutics's SIR currently stands at 4.73. In other words for every 100,000 RAPT Therapeutics shares traded daily on the market, roughly 4730 shares are currently held short.

However RAPT Therapeutics's short interest can also be evaluated against the total number of RAPT Therapeutics shares, or, against the total number of tradable RAPT Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case RAPT Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 RAPT Therapeutics shares in existence, roughly 40 shares are currently held short) or 0.0797% of the tradable shares (for every 100,000 tradable RAPT Therapeutics shares, roughly 80 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against RAPT Therapeutics.

Find out more about how you can short RAPT Therapeutics stock.

RAPT Therapeutics share dividends

We're not expecting RAPT Therapeutics to pay a dividend over the next 12 months.

RAPT Therapeutics overview

RAPT Therapeutics, Inc. , a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company's lead inflammation drug candidate is RPT193 to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. It is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1 that are in the discovery stage of development. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc.

Frequently asked questions

What percentage of RAPT Therapeutics is owned by insiders or institutions?
Currently 3.423% of RAPT Therapeutics shares are held by insiders and 81.206% by institutions.
How many people work for RAPT Therapeutics?
Latest data suggests 68 work at RAPT Therapeutics.
When does the fiscal year end for RAPT Therapeutics?
RAPT Therapeutics's fiscal year ends in December.
Where is RAPT Therapeutics based?
RAPT Therapeutics's address is: 561 Eccles Avenue, South San Francisco, CA, United States, 94080
What is RAPT Therapeutics's ISIN number?
RAPT Therapeutics's international securities identification number is: US75382E1091
What is RAPT Therapeutics's CUSIP number?
RAPT Therapeutics's Committee on Uniform Securities Identification Procedures number is: 75382E109

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site